Impact of the Combined Therapy Deflazacort+Etoricoxib in Managing Seronegative Polyarthrtitis in General Medicine
Abstract:
Experiencing pain is among those experiences that mostly tend to undermine the quality of life, for the discomfort directly provoked, for the functional impotency generated, for the need of absence from work, of access to clinics for visits or check-ups and for the need to take medicine with the risk of side effects and increased healthcare bills. Management of a patient with pain has significant impact on general medicine, 60% of visits to primary care clinics are due to pain (IPSE study). Seronegative polyarthritis assumes significant and peculiar relevance, since it is characterized by significant impairment of the quality of life, as the pain affects multiple joints and therefore prevents the patient from carrying out various activities. Furthermore, this disorder often affects young people who may suffer the most from the difficulty in carrying out daily tasks due to pain. Pain control strategies, according to the most recent scientific evidence, include the first-line use of analgesics (paracetamol and NSAIDs) in monotherapy, however in the pathological condition object of this study, it is often necessary to use high-dose analgesics to obtain a benefit, often with side effects or drug interactions with ongoing therapies. We therefore investigated the efficacy and safety of a combination therapeutic strategy with a low dosage using two drugs with complementary mechanisms of action, a corticosteroid and an inhibitor COX-2 selective. Within the two classes we chose: Deflazacort at a dosage of 12 mg/day and Etoricoxib 60 mg/day for 7 days.
